WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) will participate in the Chardan 10th Annual Healthcare Conference on October 20, giving investors an opportunity to hear from management as the Wayne-based biotechnology company advances experimental treatments for rare skin diseases and vascular anomalies.
Company executives are scheduled to participate in a fireside chat at 1:45 p.m. Eastern Time on Tuesday.
Palvella is developing drug candidates through its proprietary QTORIN platform, with an emphasis on conditions for which no U.S. Food and Drug Administration-approved therapies are available.
Its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, is being developed for microcystic lymphatic malformations, cutaneous venous malformations and clinically significant angiokeratomas.
The company is also developing QTORIN pitavastatin for disseminated superficial actinic porokeratosis, a chronic skin disorder.
Palvella remains a clinical-stage company, with its development programs focused on establishing potential treatment options for patients with serious, rare conditions.
The October 20 presentation will be available through a live webcast in the Events and Presentations section of the company’s website at www.palvellatx.com.
An archived recording is expected to remain accessible for approximately 90 days following the conference.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.